Search

Competing Interests: Funding Support and Author Disclosures Dr Pareek is on advisory boards for AstraZeneca and Janssen-Cilag; and has received speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, and Janssen-Cilag. Dr Khera has received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (grant K23HL153775) outside of the submitted work. Dr Miller is a consultant for Eidos, Pfizer, Siemens, Alnylam, and Roivant; and has received grant support from Eidos, Pfizer, and Argospect. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

How to develop highly informative serology assays to evaluate the quality of immune protection against coronavirus disease‐19 (COVID‐19) has been a global pursuit over the past years. Here, a microfluidic high‐plex immuno‐serolomic assay is developed to simultaneously measure50 plasma or serum samples for50 soluble markers including 35proteins, 11 anti‐spike/receptor binding domian (RBD) IgG antibodies spanningmajor variants, and controls. This assay demonstrates the quintuplicate test in a single run with high throughput, low sample volume, high reproducibilityand accuracy. It is applied to the measurement of 1012 blood samples including in‐depth analysis of sera from 127 patients and 21 healthy donors over multiple time points, either with acute COVID infection or vaccination. The protein analysis reveals distinct immune mediator modules that exhibit a reduced degree of diversity in protein‐protein cooperation in patients with hematologic malignancies or receiving B cell depletion therapy. Serological analysis identifies that COVID‐infected patients with hematologic malignancies display impaired anti‐RBD antibody response despite high level of anti‐spike IgG, which can be associated with limited clonotype diversity and functional deficiency in B cells. These findings underscore the importance to individualize immunization strategies for these high‐risk patients and provide an informative tool to monitor their responses at the systems level. [ABSTRACT FROM AUTHOR]

Interactions between the medical community, government, and the wider public during the COVID-19 pandemic have been an important consideration throughout the pandemic response. Attitudes towards vaccinations, in particular, have been especially complex. From the discordance of political and healthcare interests to vaccine hesitancy, there are an array of perspectives on both the delivery and administration of the vaccine. However, in a time of crisis, coherent voices need to prevail. Clinicians need to be encouraged to vocalize their expertise and lived experiences beyond the bedside. Gaps in clinician involvement with decision-making bodies have led to an erosion of trust between the public and healthcare authorities. In this commentary, we argue that it is important that medical professionals are supported in their advocacy, to act as a bridge between reliable and unbiased healthcare information and the wider community, to promote public trust, and to combat medical misinformation. [ABSTRACT FROM AUTHOR]